Used in targeted cancer therapy, particularly for solid tumors and hematologic malignancies expressing NCAM1 (CD56), such as small cell lung cancer, neuroblastoma, and multiple myeloma. Functions as a monoclonal antibody that binds to CD56 on cancer cells, enabling immune-mediated destruction and serving as a delivery vehicle for cytotoxic agents when conjugated. Investigated in antibody-drug conjugates (ADCs) to enhance tumor-specific drug delivery while minimizing damage to healthy tissues. Also utilized in diagnostic and research settings to detect CD56 expression in tissue samples and flow cytometry.